U.S. Insulin Market

U.S. Insulin Market 

• Uniform massive 5-7-fold U.S. insulin price increases in the decade-plus since Medicare Part D began
• Despite severe competition among numerous similar products
  • Many insulins on the U.S. market for decades
• Severe U.S. patient and family harm
  • Diabetes is the highest spending U.S. brand drug category
  • Rising U.S. deaths from unaffordable insulin
  • Diabetics traveling to abroad for cheaper black market insulin

Two Key Whistleblower Insulins": Sanofi's Lantus and Eli Lilly's Humulin

Sanofi's Lantus (long-acting insulin, on U.S. market since 2000)

• 2005 Reported U.S. Sales: $846 million
• 2017 Reported U.S. Sales: $4.0 billion
• 2017 U.S. Sales WITHOUT Price Increases: $1.8 billion
• A top-spending drug in Medicare Part D
• Cumulative harm since start of Part D: $21.0+ billion
  • Link to Lantus' Whistleblower price 6-FOLD price increase table 
  • Link to Lantus' Whistleblower cumulative harm chart

Eli Lilly’s Humulin (on U.S. market since 1982)

• 2005 Reported U.S. Sales: $411 million
• 2017 Reported U.S. Sales: $885 million
• U.S. Clinical Use/Prescriptions DOWN -60% since 2005
• 2017 U.S. Sales WITHOUT Price Increases: $173 million
• Cumulative harm since start of Part D: $4.1 billion
  • Link to Humulin Whistleblower 6-FOLD price increase table
  • Link to Humulin’s Whistleblower cumulative harm chart